MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN
MacroGenics reported positive interim Phase 1 data for MGC026, a B7-H3-directed ADC, presented at the ESMO 2026 Congress. In heavily pretreated SCCHN patients, MGC026 achieved a 27% best overall response rate (6/22) with a 64% disease control rate, and no treatment-related discontinuations, ILD, pneumonitis or ocular toxicity were observed. Across the dose-escalation population, confirmed ORR was 29% with durable responses (median DOR 10.2 months), supporting selection of 7.5 mg/kg Q3W for expansion cohorts.
Key figures
- Drug Name
- MGC026
- Phase Of Trial
- Phase 1
- Orr scchn
- 27% (6/22, 4 confirmed + 2 unconfirmed PRs)
- Selected dose
- 7.5 mg/kg Q3W
- Safety population
- 85
- Stage2 data timing
- mid-2027
- Grade3plus trae all
- 51%
- Orr dose escalation
- 29% confirmed (5/17)
- Grade3plus trae scchn
- 48%
- Front line combo start
- early 2027
- Disease control rate scchn
- 64% (14/22)
- Median duration of response
- 10.2 months
- Disease control rate escalation
- 65% (11/17)
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.